A technique for promoting the assimilation of an oligosaccharide such as an HMO by an intestinal bacterium, especially a bifidobacterial strain, is provided. As a first aspect, a composition for promoting the assimilation of an oligosaccharide containing a tocopherol is provided. As a second aspect, a nutritional composition (excluding breast milk) containing an oligosaccharide and a tocopherol is provided. The tocopherol in the aspects contains one, two or more kinds selected from the group consisting of β-tocopherol, γ-tocopherol and δ-tocopherol. The oligosaccharide in the aspects is preferably a human milk oligosaccharides. The mass ratio of the δ-tocopherol content to the β-tocopherol content (δ/β) in the aspects is preferably 5 or more, and the mass ratio of the γ-tocopherol content to the δ-tocopherol content (γ/δ) is preferably 8.8 or less.
This pasteurized milk beverage which contains milk protein and calcium, which has a pH at 25°C of 5.0 or less, in which the milk protein contains whey protein and the whey protein content is 40 mass% or more with respect to the total mass of the proteins contained in the pasteurized milk beverage, and which contains a phosphate and an acidified milk stabilizer has good solution stability despite containing milk protein and calcium and having a low pH.
This bacterium is Bifidobacterium bifidum MCC2085 (NITE BP-03881). This composition contains the bacterium. The composition is a food or beverage composition. The food or beverage composition is a probiotic composition or a nutritional composition. The method for producing a composition includes a step for mixing the bacterium with a raw material other than the bacterium.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23C 9/00 - Préparations à base de laitLait en poudre ou préparations à base de lait en poudre
A23C 9/127 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant des micro-organismes de la famille des lactobactériacées et d'autres micro-organismes ou des enzymes, p. ex. kéfir, koumiss
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
This serotonin production promoting composition contains one or more types selected from bacteria that are Bifidobacterium bifidum MCC2085 (NITE BP-03881), cultures of the bacteria, and treated products of the bacteria. The serotonin production promoting composition contains one or more types selected from bacteria that are Bifidobacterium longum subspecies infantis M-63 (NITE BP-02623), cultures of the bacteria, and treated products of the bacteria.
This fermented food, obtained by fermenting a raw material composition comprising bifidobacteria, Lactococcus bacteria, and an iron-containing compound, exhibits excellent bifidobacteria survival.
The present invention addresses the problem of providing bacteria which belong to Lactobacillus helveticus and which have an excellent IFN production inducing effect. Provided are bacteria that activate a plasmacytoid dendritic cells (pDC) and/or a myeloid dendritic cells (mDC) and that are capable of inducing I-type IFN production, said bacteria being classified as Lactobacillus helveticus and inducing I-type IFN production which is at least 1.5 times that of Lactobacillus helveticus SBT2171 (accession number: Ferm BP-5445).
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention provides a composition comprising Bifidobacterium, preferably Bifidobacterium breve or Bifidobacterium longum sub. infantis. The composition is used for reducing PLIN4 gene expression and/or for preventing, improving, and/or treating diseases caused by PLIN4 overexpression and/or lipid droplets accumulation.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention addresses the problem of providing a novel method for producing a solid food. The solution to the problem is a method for producing a solid food, the method comprising: a filling step in which a container is filled with a powder including lipid and sugar; and a moist-heat treatment step in which, after the filling step, the powder is subjected to a moist-heat treatment under conditions of a relative humidity of 10% or more and a temperature of 80°C or more.
The present invention addresses the problem of providing a technology for anti-obesity. This problem is solved by an anti-obesity composition containing a peptide comprising Leu-Asp-Gln-Trp (SEQ ID NO: 1), an anti-obesity composition containing a peptide comprising Leu-Lys-Pro-Thr-Pro-Glu-Gly-Asp-Leu-Glu-Ile-Leu (SEQ ID NO: 2), or an anti-obesity composition containing a peptide comprising Leu-Asp-Gln-Trp (SEQ ID NO: 1) and a peptide comprising Leu-Lys-Pro-Thr-Pro-Glu-Gly-Asp-Leu-Glu-Ile-Leu (SEQ ID NO: 2).
The present invention addresses the problem of providing a novel protein beverage in which sedimentation of heat-sterilized separated soybean protein is suppressed, and a method for producing the same. The present invention, which solves the above problem, is a protein-containing beverage which comprises separated soybean protein and tofu and in which the total mass of protein relative to the total mass of the protein-containing beverage is greater than 6 mass%.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
29 - Viande, produits laitiers et aliments préparés ou conservés
30 - Aliments de base, thé, café, pâtisseries et confiseries
32 - Bières; boissons non alcoolisées
Produits et services
Chemicals; protein (raw material); oligosaccharides; peptide
(raw material); lactulose (raw material); bifidobacteria for
use in the manufacture of food and beverages; lactobacillus
for use in the manufacture of food and beverages;
bifidobacteria strains for use in the manufacture of food
and beverages; lactobacillus strains for use in the
manufacture of food and beverages; microorganisums
(bacteria, bacteria powder) for use in the manufacture of
food and beverages; cultures of microorganisms for use in
the manufacture of food and beverages; bacteria for use in
food manufacture; bacteria strain for use in food
manufacture; powdered bacteria for use in the manufacture of
animal feed; bacterial strains for use in the manufacture of
animal feed; cultures of microorganisms, other than for
medical and veterinary use; plant growth regulating
preparations; fertilizers; artificial sweeteners for
industrial purposes; flour and starch for industrial
purposes; biological preparations for use in industry and
science; glue and adhesives for industrial purposes. Pharmaceutical preparations and substances; reagent paper
for medical purposes; oiled paper for medical purposes;
adhesive tapes for medical purposes; drug delivery agents in
the form of edible wafers for wrapping powdered
pharmaceuticals; gauze for dressings; empty capsules for
pharmaceuticals; eyepatches for medical purposes; ear
bandages; menstruation bandages; sanitary tampons; sanitary
napkins; sanitary panties; absorbent cotton; adhesive
plasters; bandages for dressings; liquid bandages;
breast-nursing pads; cotton swabs for medical use; dental
materials; diapers; diaper covers; fly catching paper;
mothproofing paper; lacteal flour for babies; lacteal flour
for infants; lacteal flour being nutritional supplements for
children; dietary supplements for human; dietetic beverages
adapted for medical purposes; dietetic foods adapted for
medical purposes; beverages for babies; beverages for
infants; nutritional supplement beverages for children; food
for babies; food for infants; food supplements for children;
dietary supplements for animals; semen for artificial
insemination; dietary fiber; cultures of microorganisms for
medical or veterinary use; powdered bacteria for medical
use; bacteria strain for medical use. Fruit-based, vegetable-based, bean-based or nut-based
snacks; edible oils and fats; milk products; milk; milk
beverages; lactic acid bacteria drinks; cream; whipped
cream; cheese; butter; powdered milk; condensed milk;
yoghurt; yoghurt drinks; meat; eggs; seafood, not live;
frozen vegetables; frozen fruits; processed meat products;
processed seafood products; processed vegetables and fruits;
jellies for food, other than confectionery; fried tofu
pieces [abura-age]; freeze-dried tofu pieces [kohri-dofu];
jelly made from devils' tongue root [konnyaku]; soya milk;
tofu; fermented soybeans [natto]; processed eggs; pre-cooked
curry stew, stew and soup mixes; dried flakes of laver for
sprinkling on rice in hot water [ochazuke-nori]; dried
flakes of fish, meat, vegetables or seaweed [furi-kake];
side-dish made of fermented soybean [name-mono]; preserved
pulses; protein milk; milk ferments for culinary purposes;
dried milk for food. Binding agents for ice cream; meat tenderizers for culinary
purposes; preparations for stiffening whipped cream;
aromatic preparations for food; tea; coffee; cocoa; ice;
sweets, confectionery and snacks made predominantly from
rice, cereal, muesli and corn; ice cream; ice pops; sorbets;
pudding; ice cream cones; jellies [confectionery]; bread;
sandwiches; steamed buns stuffed with minced meat
[chuka-manjuh]; hamburger sandwiches; fresh pizzas; hot dog
sandwiches; meat pies; seasonings; spices; ice cream mixes;
sherbet mixes; soft serve ice cream mixes; unroasted coffee;
processed cereals; processed grains; chocolate spreads;
Chinese stuffed dumplings; Chinese steamed dumplings; sushi;
fried balls of batter mix with small pieces of octopus
[takoyaki]; boxed lunches consisting of rice, with added
meat, fish or vegetables; ravioli; yeast powder; fermented
malted rice [koji]; yeast; baking powder; instant
confectionery mixes; pasta sauce; gluten for food; flour;
by-product of rice for food [sake lees]; husked rice; husked
oats; husked barley; edible paper; confectionery containing
lactulose. Beers; soft drinks; fruit drinks; vegetable juices
[beverages]; extracts of hops for making beer; whey
beverages; non-alcoholic essences for making beverages;
soya-based beverages, other than milk substitutes.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
29 - Viande, produits laitiers et aliments préparés ou conservés
30 - Aliments de base, thé, café, pâtisseries et confiseries
32 - Bières; boissons non alcoolisées
Produits et services
Chemicals; protein (raw material); oligosaccharides; peptide
(raw material); lactulose (raw material); bifidobacteria for
use in the manufacture of food and beverages; lactobacillus
for use in the manufacture of food and beverages;
bifidobacteria strains for use in the manufacture of food
and beverages; lactobacillus strains for use in the
manufacture of food and beverages; microorganisums
(bacteria, bacteria powder) for use in the manufacture of
food and beverages; cultures of microorganisms for use in
the manufacture of food and beverages; bacteria for use in
food manufacture; bacteria strain for use in food
manufacture; powdered bacteria for use in the manufacture of
animal feed; bacterial strains for use in the manufacture of
animal feed; cultures of microorganisms, other than for
medical and veterinary use; plant growth regulating
preparations; fertilizers; artificial sweeteners for
industrial purposes; flour and starch for industrial
purposes; biological preparations for use in industry and
science; glue and adhesives for industrial purposes. Pharmaceutical preparations and substances; reagent paper
for medical purposes; oiled paper for medical purposes;
adhesive tapes for medical purposes; drug delivery agents in
the form of edible wafers for wrapping powdered
pharmaceuticals; gauze for dressings; empty capsules for
pharmaceuticals; eyepatches for medical purposes; ear
bandages; menstruation bandages; sanitary tampons; sanitary
napkins; sanitary panties; absorbent cotton; adhesive
plasters; bandages for dressings; liquid bandages;
breast-nursing pads; cotton swabs for medical use; dental
materials; diapers; diaper covers; fly catching paper;
mothproofing paper; lacteal flour for babies; lacteal flour
for infants; lacteal flour being nutritional supplements for
children; dietary supplements for human; dietetic beverages
adapted for medical purposes; dietetic foods adapted for
medical purposes; beverages for babies; beverages for
infants; nutritional supplement beverages for children; food
for babies; food for infants; food supplements for children;
dietary supplements for animals; semen for artificial
insemination; dietary fiber; cultures of microorganisms for
medical or veterinary use; powdered bacteria for medical
use; bacteria strain for medical use. Fruit-based, vegetable-based, bean-based or nut-based
snacks; edible oils and fats; milk products; milk; milk
beverages; lactic acid bacteria drinks; cream; whipped
cream; cheese; butter; powdered milk; condensed milk;
yoghurt; yoghurt drinks; meat; eggs; seafood, not live;
frozen vegetables; frozen fruits; processed meat products;
processed seafood products; processed vegetables and fruits;
jellies for food, other than confectionery; fried tofu
pieces [abura-age]; freeze-dried tofu pieces [kohri-dofu];
jelly made from devils' tongue root [konnyaku]; soya milk;
tofu; fermented soybeans [natto]; processed eggs; pre-cooked
curry stew, stew and soup mixes; dried flakes of laver for
sprinkling on rice in hot water [ochazuke-nori]; dried
flakes of fish, meat, vegetables or seaweed [furi-kake];
side-dish made of fermented soybean [name-mono]; preserved
pulses; protein milk; milk ferments for culinary purposes;
dried milk for food. Binding agents for ice cream; meat tenderizers for culinary
purposes; preparations for stiffening whipped cream;
aromatic preparations for food; tea; coffee; cocoa; ice;
sweets, confectionery and snacks made predominantly from
rice, cereal, muesli and corn; ice cream; ice pops; sorbets;
pudding; ice cream cones; jellies [confectionery]; bread;
sandwiches; steamed buns stuffed with minced meat
[chuka-manjuh]; hamburger sandwiches; fresh pizzas; hot dog
sandwiches; meat pies; seasonings; spices; ice cream mixes;
sherbet mixes; soft serve ice cream mixes; unroasted coffee;
processed cereals; processed grains; chocolate spreads;
Chinese stuffed dumplings; Chinese steamed dumplings; sushi;
fried balls of batter mix with small pieces of octopus
[takoyaki]; boxed lunches consisting of rice, with added
meat, fish or vegetables; ravioli; yeast powder; fermented
malted rice [koji]; yeast; baking powder; instant
confectionery mixes; pasta sauce; gluten for food; flour;
by-product of rice for food [sake lees]; husked rice; husked
oats; husked barley; edible paper; confectionery containing
lactulose. Beers; soft drinks; fruit drinks; vegetable juices
[beverages]; extracts of hops for making beer; whey
beverages; non-alcoholic essences for making beverages;
soya-based beverages, other than milk substitutes.
13.
COMPOSITION FOR PROMOTING PRODUCTION OF AROMATIC LACTIC ACID COMPOUNDS
The present invention addresses the problem of providing: a composition that can be applied to a specific use such as a composition for promoting the production of aromatic lactic acid compounds or a composition for obtaining effects based on promoting the production of aromatic lactic acid compounds. The foregoing problem is solved by a composition containing: a nucleic acid metabolite such as hypoxanthine; and Bifidobacterium bacteria such as Bifidobacterium breve.
C12P 17/12 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'azote comme unique hétéro-atome du cycle contenant un hétérocycle à six chaînons
The present invention addresses the problem of providing a new functionality of Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623). To a composition to be administered to healthy newborns or infants born in full term, one or more selected from Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623) cells, a culture of the bacterium and a treated product of the bacterium are added as an active ingredient. This composition is used to promote the establishment of a bacterium belonging to the genus Bifidobacterium in the intestinal microflora, to promote maturation of intestinal tract function, to inhibit regurgitation of milk, or to regulate immune function.
A peptide which can be easily taken on a daily basis and which has few side effects and has various actions and a composition containing the peptide as an active ingredient are provided. A peptide having the amino acid sequence of (a) or (b) below is provided. (a) The amino acid sequence of SEQ ID NO: 1 (Asn-Leu-Pro-Pro-Leu-Thr). (b) An amino acid sequence in which one or several amino acids are substituted, deleted or added in the amino acid sequence of SEQ ID NO: 1. Moreover, a composition containing the peptide as an active ingredient is also provided.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
16.
COFFEE CONTAINING MILK-DERIVED INGREDIENT, COFFEE EXTRACT HAVING CONDENSED AROMA, AND PRODUCTION METHODS THEREFOR
The present invention addresses the problem of providing: a coffee containing a milk-derived ingredient and providing sensation of typical coffee's aroma and flavor; and a production method for the coffee. This production method is for a coffee containing a milk-derived ingredient, the method comprising: an aroma condensate obtaining step for bringing roasted and ground coffee beans into contact with water vapor, and cooling the obtained water vapor containing aroma ingredients derived from the coffee beans to obtain an aroma condensate; a coffee extract-obtaining step for bringing the roasted and ground coffee beans that have been subjected to the aroma condensate obtaining step into contact with water to obtain a coffee extract; and a mixing step for mixing the aroma condensate, the coffee extract, and a milk-derived ingredient together to obtain the coffee containing the milk-derived ingredient, wherein in the aroma condensate obtaining step, the aroma condensate is obtained such that the percentage of the mass of the aroma condensate with respect to the mass of the roasted and ground coffee beans is more than 5 mass% but less than 30 mass%.
The present invention addresses the problem of providing a food-applicable antioxidant peptide and an antioxidant composition containing same. The present invention provides a peptide comprising the amino acid sequence of Gln-Pro-Glu-Val-Met and an antioxidant composition containing said peptide.
The present invention addresses the problem of providing a fermentation composition having new nutritional properties or palatability. Provided is a fermentation composition obtained by fermenting a milk raw material containing a whey raw material, the fermentation composition containing lactic acid and acetic acid, wherein the ratio of the mass of the acetic acid to the mass of the lactic acid is 0.4 or more.
A23C 9/127 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant des micro-organismes de la famille des lactobactériacées et d'autres micro-organismes ou des enzymes, p. ex. kéfir, koumiss
A23C 21/02 - Petit-laitPréparations à base de petit-lait contenant des micro-organismes ou des enzymes, ou traités à l'aide de ceux-ci
The present invention addresses the problem of providing technology for heightening a small intestinal absorption property of a peptide having physiological functionality. This problem is solved via a composition containing a peptide composed of amino acid sequence (a), and one or two or more selected from the group consisting of peptides composed of amino acid sequence (b) or (c). Preferably, said one or two or more peptides selected from the group consisting of peptides composed of amino acid sequence (b) or (c) include one or two or more selected from the group consisting of peptides composed of amino acid sequences (d)-(f). (a) Val-Pro (b) Xaa-Xaa-Val-Pro (c) Val-Pro-Xaa (d) Leu-Pro-Val-Pro (e) Val-Pro-Asn (f) Val-Pro-Gln
The present invention addresses the problem of providing a feature for promoting utilization of an oligosaccharide having a lacto-N-neotetraose skeleton in Bifidobacterium breve. The present invention provides a composition for promoting utilization of an oligosaccharide having a lacto-N-neotetraose skeleton in Bifidobacterium breve, the composition containing one or more saccharides selected from monosaccharides and disaccharides.
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
C12N 1/38 - Stimulation chimique de la croissance ou de l'activité par addition de composés chimiques qui ne sont pas des facteurs essentiels de croissanceStimulation de la croissance par élimination d'un composé chimique
An object is to provide a prebiotic which efficiently proliferates a butyrate-producing bacterium. An oligosaccharide which is composed of β-D-mannuronic acid and/or α-L-guluronic acid and which has an unsaturated form of β-D-mannuronic acid residue or α-L-guluronic acid residue at the non-reducing end or a salt thereof is used as an active ingredient of a prebiotic composition for a butyrate-producing bacterium. The oligosaccharide can be produced by causing an alginate lyase to act on alginic acid and/or a salt thereof or a hydrolysate thereof and thus obtaining a degradation product of alginic acid.
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
Provided is a beverage that contains Lacticaseibacillus paracasei bacteria and non-milkfat solid matter, wherein the non-milkfat solid matter constitutes less than 8.0 mass% of the total mass of the beverage.
A23C 9/123 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes ne comportant que des micro-organismes de la famille des lactobactériacéesYoghourt
A23C 9/13 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant l'emploi d'additifs
Provided is fermented milk that contains Lacticaseibacillus paracasei bacteria and milk fat, wherein the milk fat constitutes at most 2.0 mass% of the total mass of the fermented milk.
A23C 9/123 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes ne comportant que des micro-organismes de la famille des lactobactériacéesYoghourt
A23C 9/13 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant l'emploi d'additifs
This antiepileptic composition contains one of or both of a bacterium of the genus Bifidobacterium and a culture thereof. The bacterium of the genus Bifidobacterium may be Bifidobacterium breve. The bacterium of the genus Bifidobacterium may be an MCC1274 strain (FERM BP-11175) of Bifidobacterium breve. The antiepileptic composition may contain one of or both of the bacterium of the genus Bifidobacterium and a culture thereof in an amount of 1×106to 1×1012 CFU/g.
The present invention addresses the problem of providing a method for obtaining a milk protein degradation product which has good emulsifiability despite a low-molecular-weight peptide. A method for producing a milk protein degradation product comprises a protein degradation step in which a proteolytic enzyme is made to act on the milk protein, wherein: the proteolytic enzyme comprises a trypsin-like endo-type protease derived from microorganisms, an endo-type protease derived from bacteria belonging to the genus Bacillus, and papain; and the number average molecular weight of the milk protein degradation product is 650 or less.
The present invention addresses the problem of providing: a new food component that inhibits production of cortisol; and a composition containing the food component. The present invention provides a composition that is for inhibiting production of cortisol, and that contains a milk-derived phospholipid.
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
A23J 7/00 - Compositions à base de phosphatides pour l'alimentation, p. ex. lécithine
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 5/38 - Médicaments pour le traitement des troubles du système endocrinien des hormones surrénales
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
An aspect is to provide an active ingredient which can improve mitochondrial function. Another aspect is to provide a composition for suppressing muscle inflammation or muscular atrophy. One, two, or more kinds selected from a bacterium of the genus Akkermansia, a culture of the bacterium and a treated product of the bacterium are used as an active ingredient in a mitochondrial function-improving composition. The composition can be preferably applied for suppressing muscle inflammation or suppressing muscular atrophy.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
28.
Cognitive Function Improving Agent, Cognitive Function Maintaining Agent, Hippocampus Function Improving Agent, and Hippocampus Function Maintaining Agent
A cognitive function-improving agent containing one or both of Bifidobacterium breve FERM BP-11175 and a culture of Bifidobacterium breve FERM BP-11175 as an active ingredient for administration to a subject who has not developed dementia is provided.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
29.
COMPOSITION FOR PROMOTING INTESTINAL TRACT DEVELOPMENT, COMPOSITION FOR IMPROVING PULMONARY FUNCTION AND COMPOSITION FOR ENHANCING IMMUNE FUNCTION
A composition for promoting development of the intestinal tract, a composition for improving lung function or a composition for improving immune function containing a bacterium belonging to Bifidobacterium longum subsp. infantis is provided. The bacterium is preferably Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623).
An object of the present technology is to provide a nutritional composition having excellent emulsion stability. The present technology provides a nutritional composition containing a protein component, a lipid, and an organic acid ester of monoglyceride, wherein the organic acid ester of monoglyceride includes two or more kinds selected from acetic acid ester of monoglyceride, citric acid ester of monoglyceride, succinic acid ester of monoglyceride, diacetyl tartaric acid ester of monoglyceride, and lactic acid ester of monoglyceride. At least one kind among the organic acid esters of monoglyceride may be succinic acid ester of monoglyceride. Further, at least one kind among the organic acid ester of monoglyceride may be diacetyl tartaric acid ester of monoglyceride.
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
A61K 31/22 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japon)
MORINAGA MILK INDUSTRY CO., LTD. (Japon)
Hitachi, Ltd. (Japon)
Inventeur(s)
Suzuki, Daisuke
Lei, Miaomei
Tamakoshi, Akiko
Yokota, Takashi
Nakamura, Kiminori
Takeda, Yasuhiro
Ehara, Tatsuya
Abrégé
A parent-and-child health study assistance system includes a data management section managing health study data used for a health study of at least one of a parent and a child in a family including a user as a family member, a level calculation section calculating a contribution level for the health study of the user based on input of the health study data, an incentive provision section providing the user with an incentive used as a profit corresponding to the contribution level, in conjunction with input of the health study data, an access control section managing an access authority to access the health study data, and an analysis result provision section providing an analysis result of analysis processing using the health study data.
G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
G06Q 30/0208 - Commerce ou échange de biens ou de services contre des incitations ou des récompenses
G16H 20/60 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant le contrôle de l’alimentation, p. ex. les régimes
G06F 21/62 - Protection de l’accès à des données via une plate-forme, p. ex. par clés ou règles de contrôle de l’accès
The purpose of the present technique is to provide a nutritional composition useful for preventing an immune dysfunction. The present technique provides a nutritional composition containing a whey protein hydrolysate. The number-average molecular weight of the whey protein hydrolysate is 100-1,200, the whey protein hydrolysate includes a fraction having a molecular weight of 200-500, and the proportion of the area of the fraction having a molecular weight of 200-500 is 10-50% with respect to the total area in the molecular weight distribution curve of the whey protein hydrolysate. The nutritional composition may be used for supplementing the nutrition of persons who are infected. Moreover, the nutritional composition may be used for supplementing the nutrition of persons in an acute phase.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 3/02 - Nutriments, p. ex. vitamines, minéraux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japon)
MORINAGA MILK INDUSTRY CO., LTD. (Japon)
Hitachi, Ltd. (Japon)
Inventeur(s)
Nakamura, Takahiro
Takemoto, Takashi
Yoshino, Masanori
Ayabe, Tokiyoshi
Kimura, Takashi
Izumi, Hirohisa
Tabata, Fuka
Abrégé
An analysis device in a parent-child health management system receives a sensor output from a sensor terminal and an answer to a questionnaire from a user terminal. At least one of parent's life information and child's life information is analyzed based on the answer to the questionnaire to generate a life information analysis result. A sensor output analysis unit generates, based on the sensor output, a sensing result including at least one of a parent-child relationship, a parent's health condition, and a child's health condition. A health estimation unit is configured to compare the life information analysis result and the sensing result with a predetermined criterion to estimate at least one of a parent-child state, a parent's state, and a child's state. An output unit is configured to select a questionnaire and advice corresponding to the estimated state and output the selected questionnaire and advice to the user terminal.
G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
longum, having utilization ability for 2′-fucosyllactose are also provided. More preferably, bacteria having utilization ability for carbohydrates arabinoxylan, arabinan, and pectic galactan; and a composition containing the bacteria are also provided. More preferably, a composition containing 2′-fucosyllactose are also provided. More preferably, a composition containing at least one carbohydrate selected from the group consisting of arabinoxylan, arabinan, pectic galactan, and oligosaccharides derived therefrom or containing at least a carbohydrate derived from a gramineous plant or a carbohydrate derived from a solanaceous plant are also provided.
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
35.
PROPHYLACTIC AGENT FOR BRAIN ATROPHY, METHOD FOR PREVENTING BRAIN ATROPHY, CULTURE, USE OF CULTURE, FOOD OR BEVERAGE, FOOD FOR PREVENTING BRAIN ATROPHY, SUPPLEMENT FOR PREVENTING BRAIN ATROPHY, AND MEDICINE FOR PREVENTING BRAIN ATROPHY
The brain atrophy suppressor contains, as an active ingredient, a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) for administration to a subject selected from a healthy individual, an individual diagnosed with mild cognitive impairment, an individual assessed as having cognitive decline and a subject at a risk of a neurodegenerative disease.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
36.
COMPOSITION FOR PROMOTING THE ASSIMILATION OF AN OLIGOSACCHARIDE
A technique for promoting the assimilation of an oligosaccharide such as an HMO by an intestinal bacterium, especially a bifidobacterial strain, is provided. As a first aspect, a composition for promoting the assimilation of an oligosaccharide containing a tocopherol is provided. As a second aspect, a nutritional composition (excluding breast milk) containing an oligosaccharide and a tocopherol is provided. The tocopherol in the aspects contains one, two or more kinds selected from the group consisting of β-tocopherol, γ-tocopherol and δ-tocopherol. The oligosaccharide in the aspects is preferably a human milk oligosaccharides. The mass ratio of the δ-tocopherol content to the β-tocopherol content (δ/β) in the aspects is preferably 5 or more, and the mass ratio of the γ-tocopherol content to the δ-tocopherol content (γ/δ) is preferably 8.8 or less.
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
37.
PROPHYLACTIC AGENT FOR BRAIN ATROPHY, METHOD FOR PREVENTING BRAIN ATROPHY, CULTURE, USE OF CULTURE, FOOD OR BEVERAGE, FOOD FOR PREVENTING BRAIN ATROPHY, SUPPLEMENT FOR PREVENTING BRAIN ATROPHY, AND MEDICINE FOR PREVENTING BRAIN ATROPHY
This prophylactic agent for brain atrophy is intended to be administered to any one subject selected from a normal person, a person who is diagnosed as having mild cognitive impairment, a person who is examined to be deteriorated in cognitive function, a subject who is at a risk of being affected by a neurodegenerative disease, and contains a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) as an active ingredient.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japon)
MORINAGA MILK INDUSTRY CO., LTD. (Japon)
Hitachi, Ltd. (Japon)
Inventeur(s)
Nakamura, Takahiro
Takemoto, Takashi
Yoshino, Masanori
Ayabe, Tokiyoshi
Kimura, Takashi
Izumi, Hirohisa
Tabata, Fuka
Abrégé
A mother and child health management system is connected to a plurality of terminals and includes: a reception unit configured to receive, as analysis information, information from each of the plurality of terminals and biological information from a medical care institution; a classification unit configured to identify, based on an analysis result of the analysis information, state values indicating a state of a mother, a state of a child, and a state between the mother and the child; an access authority management section configured to identify, based on each of the state values, a community to which a family including a user of the each of the plurality of terminals belongs, and configured to provide the terminal with an access authority to receive a display of a solution related to the community; and a display unit configured to display the solution related to the community on the terminal.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
39.
THREONIC-ACID-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME
A problem addressed is to provide a useful means for increasing muscle mass. A composition containing threonic acid, one or more bacteria selected from Bifidobacterium spp., Lactobacillus spp., Lacticaseibacillus spp., Lactiplantibacillus spp., Limosilactobacillus spp., Levilactobacillus spp., Ligilactobacillus spp., and Latilactobacillus spp., and one or more selected from cultures of the aforementioned bacteria is used to increase muscle mass. Such a composition is produced through, e.g., a method that includes a step for culturing one or more bacteria selected from the aforementioned bacteria in ascorbic-acid-containing medium and a step for recovering a threonic-acid-containing fraction from the culture after culturing.
The present invention addresses the problem of developing a more efficient method for producing aloe extract. The present invention provides a method for producing aloe extract, the method including the following steps: a step for obtaining an extract from dried aloe mesophyll through a supercritical fluid extraction method; and a step for carrying out oil-water separation on the extract obtained in the aforementioned step, and obtaining the resultant oil phase as an aloe extract.
According to the invention, a novel Bifidobacterial strain having an ability of assimilating two or more kinds of HMO is provided. The strain is selected from the group consisting of Bifidobacterium longum subspecies infantis (NITE BP-03068), Bifidobacterium bifidum (NITE BP-03058) and Bifidobacterium bifidum (NITE BP-03067).
A23C 9/123 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes ne comportant que des micro-organismes de la famille des lactobactériacéesYoghourt
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
According to the invention, a composition which can promote the growth of a Bifidobacterial strain which can be a good bacterium is provided. The composition contains a human milk oligosaccharide mixture containing lacto-N-neotetraose, lacto-N-tetraose, 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose and Bifidobacterium longum subspecies infantis.
A23C 9/152 - Préparations à base de laitLait en poudre ou préparations à base de lait en poudre comportant des additifs
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
The purpose of the present technique is to provide a nutritional composition for improving the intestinal environment. The present technique provides a nutritional composition that contains indigestible dextrin and inulin, wherein the ratio by mass of the indigestible dextrin in prebiotic component is 100 times or less than the ratio by mass of inulin in the prebiotic component. Preferably, the ratio by mass of the indigestible dextrin in the prebiotic component is 0.2-100 times inclusive than the ratio by mass of inulin in the prebiotic component.
A23L 29/244 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des agents gélifiants ou épaississants d'origine végétale à partir de bulbes, de tubercules ou de racines, p. ex. glucomannane
A23L 29/30 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sirops d'hydrate de carboneAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sucresAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des alcools de sucre, p. ex. du xylitolAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des hydrolysats d'amidon, p. ex. de la dextrine
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p. ex. de fibres diététiques
A23L 33/22 - Parties fibreuses broyées de plantes, p. ex. bagasse ou pulpe
A23L 33/26 - Polyesters de polyol, p. ex. polyesters de sucrosePolymères synthétiques de sucre, p. ex. polydextrose
The present invention addresses the problem of providing a nutritional composition that has high calories and that has excellent emulsification stability even when the contained amount of an emulsifier is less. This nutritional composition contains lipids, carbohydrates, and an emulsifier. The contained amount of the lipids in the nutritional composition is 3.5 g/100kcal or more. The contained amount of the emulsifier in the nutritional composition is 0.60 g/100kcal or less. In the lipids, the proportion of medium chain fatty acids in the total constitutional fatty acids is 20 mass% or more.
A23D 7/00 - Compositions à base d'huiles ou de graisses comestibles contenant une phase aqueuse, p. ex. margarines
A23D 7/005 - Compositions à base d'huiles ou de graisses comestibles contenant une phase aqueuse, p. ex. margarines caractérisées par des ingrédients autres que des triglycérides d'acides gras
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
The present invention provides a protein-containing composition that can be ingested without reducing the intake, and without placing a burden on the kidney and the liver. Provided is a protein-containing composition for enteral intake, the composition including at least 81% by mass micellar casein with respect to the total protein, which composition is for ingestion by a subject requiring suppression or prevention of a decline(s) in renal function and/or liver function.
An aspect is to provide a prebiotic for growing a butyrate-producing bacterium. A prebiotic composition for a butyrate-producing bacterium includes alginic acid and/or a salt thereof having an average molecular weight of 10000 or less.
The present invention addresses the problem of providing a technique for promoting various bacteria of the genus Bifidobacterium in intestinal flora. A prebiotic composition for bacteria of the genus Bifidobacterium is obtained by combining 1-kestose and galactooligosaccharide. The composition can proliferate one or two or more kinds of bacteria of the genus Bifidobacterium selected from the group consisting of Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium bifidum.
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23C 9/152 - Préparations à base de laitLait en poudre ou préparations à base de lait en poudre comportant des additifs
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
An electrolyzed water generator according to one embodiment is provided with: a first electrolysis cell which is provided with an electrolyte solution chamber, a positive electrode chamber that is divided from the electrolyte solution chamber by means of a first diaphragm, a negative electrode chamber that is divided from the electrolyte solution chamber by means of a second diaphragm, a positive electrode that is arranged in the positive electrode chamber so as to face the first diaphragm, a first negative electrode that is arranged in the negative electrode chamber so as to face the second diaphragm, a second negative electrode that is arranged in the electrolyte solution chamber so as to face the positive electrode with the first diaphragm being interposed therebetween, and a third diaphragm that is arranged between the second negative electrode and the first diaphragm so as to divide the inside of the electrolyte solution chamber into a first electrolyte solution chamber which is on the positive electrode chamber side and a second electrolyte solution chamber which is on the negative electrode chamber side; a first feeding unit which feeds power to the positive electrode, the first negative electrode and the second negative electrode; a switch which applies a current from the feeding unit to the first negative electrode and/or the second negative electrode; and a first product water mixing unit which forms a first mixed product water by mixing product water at the positive electrode and product water at the negative electrode with each other, said product waters being obtained by electrolyzing an electrolyte solution in the first electrolysis cell.
A method for producing a meat-like food product comprises the steps of: mixing ingredients comprising tofu, water-soluble dietary fibers derived from grain, and gluten to prepare a dough; shaping the dough into a shaped product; and heating the shaped product.
The present invention provides: a peptide that can be readily consumed on a daily basis and has various effects but few side effects; and a composition that contains the peptide as an active ingredient. Provided is a peptide that comprises the amino acid sequence of (a) or (b). (a) The amino acid sequence of SEQ ID NO:1 (Asn-Leu-Pro-Pro-Leu-Thr). (b) An amino acid sequence produced from the amino acid sequence of SEQ ID NO:1 by adding, deleting, or replacing one or more amino acids. Also provided is a composition that contains the peptide as an active ingredient.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 1/12 - Procédés généraux de préparation de peptides par hydrolyse
C12P 21/06 - Préparation de peptides ou de protéines préparés par hydrolyse d'une liaison peptidique, p. ex. hydrolysats
The present invention addresses the problem of providing a technology for improving quality of life (QOL), preferably, to provide a technology for ameliorating insomnia, for ameliorating fatigue, or for improving gastrointestinal regulation. This problem is solved by a composition for improving QOL, which contains Lactobacillus helveticus.
The present invention addresses the problem of providing a technique for further promoting the proliferation of a plurality of major species of bacteria belonging to the genus Bifidobacterium in the intestinal flora. Oligosaccharides including galactooligosaccharide, lactulose, and raffinose are used as prebiotics for bacteria belonging to the genus Bifidobacterium including Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium bifidum. Provided is a composition containing the oligosaccharides and the bacteria belonging to the genus Bifidobacterium. Moreover, provided is a composition for promoting the proliferation of bacteria belonging to the genus Bifidobacterium, the composition containing the oligosaccharides.
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A23C 9/152 - Préparations à base de laitLait en poudre ou préparations à base de lait en poudre comportant des additifs
A23L 29/30 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sirops d'hydrate de carboneAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sucresAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des alcools de sucre, p. ex. du xylitolAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des hydrolysats d'amidon, p. ex. de la dextrine
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p. ex. de fibres diététiques
54.
Composition for Babies and Infants for Improving Memory Ability in Childhood
A problem of the invention is to provide a technique for improving memory ability in later childhood, and the problem is solved by a composition for an infant and/or child for improving memory ability in later childhood, wherein the composition contains Bifidobacterium longum subsp. infantis as an active ingredient.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention addresses the problem of providing a peptide having excellent dipeptidyl peptidase-IV (DPP-IV) inhibitory activity. An oligopeptide including any of the sequences described in (a) to (h) below. These oligopeptides may be an effective ingredient of the DPP-IV inhibitor. (a) Leu-Pro-Val, (b) Ile-Pro-Thr, (c) Pro-Pro-Gln, (d) Ala-Pro-Phe, (e) Pro-Pro-Leu, (f) Pro-Pro-Phe, (g) Ala-Pro-Ser, (h) Leu-Pro-Val-Pro
Provided is a frozen dessert in which the formation of ice on the surface thereof is suppressed during storage in a frozen state. This frozen dessert is formed of a composition that contains at least one specific component selected from the group consisting of pullulan, tremel gum, starch, trehalose, powdered candy and gelatin, and water.
A23G 9/24 - Détails, éléments constitutifs ou accessoires d'appareils dans la mesure où ils ne sont pas spécifiques à un seul des groupes précédents pour enrober ou fourrer les produits
A method for producing a frozen dessert according to the present invention comprises a step in which a first frozen dessert material (11) is inserted into a mold (2), a portion thereof contacting the inner surface of the mold (2) is hardened to form a shell layer (11b), a second frozen dessert material (12) is then inserted into the mold (2), a remaining portion (11c) of the first frozen dessert material is hardened, and a frozen dessert molded using a mold is obtained. The viscosity of the first frozen dessert material at the insertion temperature is 4000 mPa·s or less, and the viscosity of the second frozen dessert material at the insertion temperature is 3000 mPa·s or less. The specific gravity of the second frozen dessert material at the insertion temperature is greater than the specific gravity of the first frozen dessert material at the insertion temperature, and the difference thereof is 0.06 or greater.
A23G 9/24 - Détails, éléments constitutifs ou accessoires d'appareils dans la mesure où ils ne sont pas spécifiques à un seul des groupes précédents pour enrober ou fourrer les produits
A23G 9/48 - Produits composites, p. ex. en couches, enrobés, fourrés
58.
COMPOSITION FOR PLASMACYTOID DENDRITIC CELL ACTIVATION
The present invention addresses the problem of providing a composition capable of maintaining, improving, or enhancing immune function by activating plasmacytoid dendritic cells (pDCs). Lactoferrin and/or a lactoferrin hydrolysate is incorporated as an active ingredient into this composition for pDC activation. The pDC activation can include an increase in one or more selected from the group consisting of the proportion of pDCs among mononuclear cells, the proportion of CD86+ cells among pDCs, the CD86 expression level in pDCs, and the HLA-DR expression level in pDCs. The composition can be ingested in the form of a food/beverage or a pharmaceutical.
An object of the present invention is to provide a technique for further promoting growth of bacteria belonging to the genus Bifidobacterium. By combining lactoferrin and/or lactoferrin hydrolyzate, and human milk oligosaccharides, a synergistic growth promoting effect of the bacteria belonging to the genus Bifidobacterium is achieved. Preferably, the human milk oligosaccharides include one or more selected from the group consisting of 2′-fucosyllactose, 3-fucosyllactose, and lactodifucotetraose. In addition, preferably, the bacteria belonging to the genus Bifidobacterium include one or more selected from the group consisting of Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium longum.
An object of the present invention is to provide a technique for preventing infection of pathogenic viruses, which cause infectious diseases in animals or humans. A nutritional composition containing lactoferrin and/or lactoferrin hydrolysate, and human milk oligosaccharide is provided. One or more human milk oligosaccharides are preferably 2′-fucosyllactose, 3-fucosyllactose, 3′-sialyllactose, and 6′-sialyllactose. The nutritional compositions of the present invention can be used for preventing infection, especially for preventing viral infection.
A61K 38/40 - Transferrines, p. ex. lactoferrines, ovotransferrines
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
The invention provides a composition which contains a bacterial powder and a fatty oil and in which caking of the bacterial powder is suppressed, a method for producing the same, and a method of preventing caking. Provided are a composition including a bacterial powder, a fatty oil, and at least one selected from the group consisting of a microscopic powder and a surfactant, wherein the bacterial powder comprises at least one selected from the group consisting of live cells of lactic acid bacteria, killed cells of lactic acid bacteria, live cells of bifidobacteria, and killed cells of bifidobacteria, a method for producing the same, and a method of preventing caking in a composition containing a fatty oil.
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present invention addresses the problem of providing prebiotics that efficiently proliferate butyric acid bacteria. The prebiotic composition for butyric acid bacteria has, as an active ingredient thereof, an oligosaccharide, or a salt thereof, that comprises a β–D–mannuronic acid and/or an α–L–gluuronic acid and has an unsaturated β–D–mannuronic acid residue or an α–L–gluuronic acid residue on a non-reducing terminal thereof. This oligosaccharide can be produced by causing alginate lyase to act on alginate and/or a salt thereof or a hydrolysate thereof and obtaining an alginate decomposition product.
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
C12P 7/40 - Préparation de composés organiques contenant de l'oxygène contenant un groupe carboxyle
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A23K 10/18 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires de micro-organismes vivants
Provided is a novel food and drink which can continuously increase the lactic acid concentration in the blood. This food and drink contains a lactic acid compound and fructose, wherein the content of the lactic acid compound is 3-75 g in terms of lactic acid, and the content of the fructose is 7-150 g.
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 29/269 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des agents gélifiants ou épaississants d'origine microbienne, p. ex. xanthane ou dextrane
66.
COMPOSITION FOR REGULATING EXPRESSION OF GENE INVOLVED IN PRODUCTION OR DEGRADATION OF COLLAGEN, ELASTIN, OR HYALURONIC ACID
The present invention addresses the problem of providing a technique for regulating expression of a gene involved in the production or degradation of collagen, elastin, or hyaluronic acid. This problem is solved by using a composition, for regulating the expression of a gene involved in the production or degradation of collagen, elastin or hyaluronic acid, which includes Bifidobacterium Breve M-16V (NITE BP-02622) or a culture supernatant thereof as an active ingredient, wherein the gene is selected from the collagen-degrading enzyme 1 gene (MMP1), the type I collagen gene (COL1A1), the elastin gene (ELN), the hyaluronic acid synthase 1 gene (HAS1), and the hyaluronic acid synthase 2 gene (HAS2).
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 9/14 - VasoprotecteursAntihémorroïdauxMédicaments pour le traitement des varicesStabilisateurs capillaires
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
The present invention addresses the problem of providing the development of a simpler, more efficient method for producing a phytosterol starting material. The present invention is a method for producing a phytosterol starting material, the method comprising a step (1) and a step (2), where step (1) is a step for obtaining a pressing residue by pressing aloe mesophyll, and step (2) is a step for obtaining a dried pressing residue by drying the pressing residue obtained in step (1).
C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
C07J 53/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par condensation avec des cycles carbocycliques ou par formation d'un cycle additionnel par une liaison directe entre deux atomes de carbone cycliques
A23L 33/11 - Stérols de plantes ou leurs dérivés, p. ex. phytostérols
A problem is to provide a prebiotic which promotes the growth of a butyrate-producing bacterium. A prebiotic composition is described that promotes the growth of a butyrate-producing bacterium which contains alginic acid and/or a salt thereof.
An object of this present invention is to provide a composition for inhibiting norovirus infection which can inhibit norovirus from infecting a human, and the object is achieved by a composition for inhibiting norovirus infection containing one or more kinds of bacteria selected from the group consisting of Bifidobacterium breve, Bifidobacterium longum subsp. infantis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium catenulatum, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus delbrueckii subsp. Bulgaricus and Lactobacillus paracasei as an active ingredient.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japon)
MORINAGA MILK INDUSTRY CO., LTD. (Japon)
HITACHI, LTD. (Japon)
Inventeur(s)
Nakamura Takahiro
Takemoto Takashi
Yoshino Masanori
Ayabe Tokiyoshi
Kimura Takashi
Izumi Hirohisa
Tabata Fuka
Abrégé
This maternal and child health management system comprises: a reception unit which connects to a plurality of terminals and receives, as analysis information, information from a terminal and biometric information from medical institutions; a classification unit which specifies, on the basis of the analysis result of the analysis information, each state value of the state of the mother, the state of the child, and the state between the mother and the child; an authority management unit which specifies, on the basis of each state value, a belonging community of the family of a user who uses a terminal, and grants access authority to receive presented solutions related to the belonging community; and a presentation unit which presents solutions related to the belonging community to the terminal.
G16H 80/00 - TIC spécialement adaptées pour faciliter la communication entre les professionnels de la santé ou les patients, p. ex. pour le diagnostic collaboratif, la thérapie collaborative ou la surveillance collaborative de l’état de santé
71.
PARENT-CHILD HEALTH MANAGEMENT SYSTEM, PARENT-CHILD HEALTH ANALYSIS DEVICE, AND PARENT-CHILD HEALTH MANAGEMENT METHOD
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japon)
MORINAGA MILK INDUSTRY CO., LTD. (Japon)
HITACHI, LTD. (Japon)
Inventeur(s)
Nakamura Takahiro
Takemoto Takashi
Yoshino Masanori
Ayabe Tokiyoshi
Kimura Takashi
Izumi Hirohisa
Tabata Fuka
Abrégé
In this parent-child health management system, an analysis device comprises: a reception unit for receiving sensor output of a sensor terminal and response of questionnaire input to a user terminal; a questionnaire analysis unit for analyzing at least one of living information of a parent and living information of a child from the response of the questionnaire to generate a living information analysis result; a sensor output analysis unit for generating, on the basis of the sensor output, a sensing result including at least one of a relationship between the parent and the child, a health condition of the parent, and a health condition of the child; a health estimation unit for comparing the living information analysis result and the sensing result with a predetermined criteria defined in advance to estimate at least one of a condition of the parent and the child, a condition of the parent, and a condition of the child; and an output unit for selecting a questionnaire and advice corresponding to the estimated state and outputting the selected questionnaire and advice to the user terminal.
G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients
G16H 80/00 - TIC spécialement adaptées pour faciliter la communication entre les professionnels de la santé ou les patients, p. ex. pour le diagnostic collaboratif, la thérapie collaborative ou la surveillance collaborative de l’état de santé
72.
COGNITIVE FUNCTION IMPROVING AGENT, COGNITIVE FUNCTION MAINTAINING AGENT, HIPPOCAMPUS FUNCTION IMPROVING AGENT, AND HIPPOCAMPUS FUNCTION MAINTAINING AGENT
Provided is a cognitive function improving agent which is administered to a subject who has not developed dementia, and which contains, as an active ingredient, one or both of Bifidobacterium breve FERM BP-11175 and a culture of Bifidobacterium breve FERM BP-11175.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
73.
PARENT-CHILD HEALTH SURVEY ASSISTANCE SYSTEM, PARENT-CHILD HEALTH SURVEY ASSISTANCE DEVICE, AND DATA PROCESSING METHOD
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japon)
MORINAGA MILK INDUSTRY CO., LTD. (Japon)
HITACHI, LTD. (Japon)
Inventeur(s)
Suzuki Daisuke
Lei Miaomei
Tamakoshi Akiko
Yokota Takashi
Nakamura Kiminori
Takeda Yasuhiro
Ehara Tatsuya
Abrégé
This parent-child health survey assistance system comprises: a data management unit that manages health survey data to be used in a health survey of at least either one of a parent and a child in a family having users as constituent members; a level calculation unit that calculates a level representing the extent of a user's health survey contribution made via the inputting of health survey data; an incentive provision unit that, in conjunction with the inputting of the health survey data, provides the user with an incentive, which is a benefit corresponding to the level; an access control unit that manages access authority for the health survey data; and an analysis result provision unit that provides analysis results from analysis which used the health survey data.
G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients
The present invention addresses the problem of providing an active ingredient capable of improving mitochondrial function. The present invention also addresses the problem of providing a composition for suppressing muscular inflammation or muscular atrophy. This mitochondrial function-improving composition contains, as an active ingredient, one or more selected from bacteria belonging to the genus Akkermansia, cultures of the bacteria, and processed products of the bacteria. The composition can be suitably applied to usage in muscular inflammation suppression and muscular atrophy suppression.
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
Provided is a composition for promoting intestinal tract development, a composition for improving pulmonary function or a composition for enhancing immune function, said composition containing a bacterium belonging to Bifidobacterium longum subspecies infantis. Preferably, the bacterium is Bifidobacterium longum subspecies infantis M-63 (NITE BP-02623).
Provided is a fermentation composition which includes (A) whey protein, (B) bifidobacterium bacteria, and (C) at least 0.05 mass% of ash content, and can suppress a decrease in the viable count of the bifidobacterium bacteria.
The present invention addresses the problem of providing a supercritical fluid extraction device capable of achieving high collection efficiency whether a target product is solid or semi-solid, and a method for manufacturing a target product using the same. A supercritical fluid extraction device (1) uses a supercritical fluid F to produce a target product p, the supercritical fluid extraction device (1) comprising: an extraction tank A which houses a raw material P of the target product p and to which the supercritical fluid F is supplied; a separation tank B that separates the target product p from the supercritical fluid F; and a collection container that houses the target product p, where the collection container C is detachably disposed inside the separation tank B.
The present invention provides a composition capable of promoting the growth of a bacterium of the genus Bifidobacterium that can act as a beneficial bacterium. This composition comprises a mixture of human milk oligosaccharides, said mixture consisting of lacto-N-neotetraose, lacto-N-tetraose, 2'-fucosyllactose, 3'-sialyllactose and 6'-sialyllactose, together with Bifidobacterium longum subspecies infantis.
A23C 9/152 - Préparations à base de laitLait en poudre ou préparations à base de lait en poudre comportant des additifs
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
The present invention provides a novel Bifidobacterium bacterium that is capable of producing at least two types of human milk oligosaccharides (HMOs). This bacterium is selected from the group consisting of bifidobacterium longum subspecies infantis (NITE BP-03068), bifidobacterium bifidum (NITE BP-03058), and bifidobacterium bifidum (NITE BP-03067).
A composition usable for a specific use, such as a composition for improving neurite outgrowth is provided. Such a composition is provided by using indole-3-lactic acid (ILA) or an indole-3-lactic acid-producing bacterium is used as an active ingredient.
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention addresses the problem of providing a composition against aging. One or more substances selected from among Bifidobacterium longum NITE BP-02621, cultures thereof, and treated products thereof are included in an anti-aging composition. The composition of the present invention preferably makes it possible to obtain an anti-aging effect by cell senescence inhibitory activity and/or mitochondrial function improvement activity. Furthermore, the composition of the present invention can be suitably used for the purpose of extending life and/or suppressing hypokinesia.
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12P 1/04 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymesProcédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes utilisant des bactéries
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
Bifidobacterium and/or lactobacilli as an active ingredient, and is used for a pre-obesity group or an obesity disease including intestinal flora in which the ratio of the phylum Firmicutes to the phylum Bacteroidetes has a high value.
A novel agent useful for improving brain function is provided. The active ingredient in this agent is a Bifidobacterium breve and/or a Bifidobacterium breve-containing cultured material is provided.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
The present invention addresses the problem of providing a protein-containing composition that can be consumed without reducing the intake and without placing stress on the kidney and liver. Provided is a protein-containing composition for enteral intake, the composition containing micellar casein in an amount of at least 81% by mass of the total protein and being designed to be taken by a subject in need of suppression or prevention of reduced renal function and/or hepatic function.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
85.
Bifidobacterium bacteria and composition including novel bifidobacterium bacteria
longum, having utilization ability for 2′-fucosyllactose are also provided. More preferably, bacteria having utilization ability for carbohydrates arabinoxylan, arabinan, and pectic galactan; and a composition containing the bacteria are also provided. More preferably, a composition containing 2′-fucosyllactose are also provided. More preferably, a composition containing at least one carbohydrate selected from the group consisting of arabinoxylan, arabinan, pectic galactan, and oligosaccharides derived therefrom or containing at least a carbohydrate derived from a gramineous plant or a carbohydrate derived from a solanaceous plant are also provided.
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
86.
Method for producing lactoferrin-containing aqueous solution
There is provided a means for sterilizing lactoferrin at a high temperature in a short time while maintaining the activity of the lactoferrin. The present technology provides a method for producing a lactoferrin-containing aqueous solution, including a sterilization step of heat-sterilizing a lactoferrin-containing aqueous solution, in which the total mass content of proteins other than lactoferrin is 1/12 or less of the mass content of lactoferrin, at a temperature of 100° C. or more. The present technology also provides a lactoferrin-containing aqueous solution in which the total mass content of proteins other than lactoferrin is 1/12 or less of the mass content of lactoferrin, and which does not contain living bacteria.
A23J 1/20 - Préparation des compositions à base de protéines pour l'alimentationOuverture des œufs par grandes quantités et séparation du jaune du blanc à partir du lait, p. ex. caséinePréparation des compositions à base de protéines pour l'alimentationOuverture des œufs par grandes quantités et séparation du jaune du blanc à partir du petit-lait
Provided are: a composition that includes bacterium powder and fatty oil and has suppressed caking of the bacterium powder; a production method; and a usage. A composition including bacterium powder, fatty oil, and at least one type selected from the group consisting of a micro-powder and a surfactant; a production method therefor; and a usage as an anti-caking agent for bacterium powder, in at least one type of composition that includes fatty oil and is selected from the group consisting of a micro-powder and a surfactant.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23C 9/123 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes ne comportant que des micro-organismes de la famille des lactobactériacéesYoghourt
The present invention addresses the problem of providing prebiotics that proliferate butyric acid bacteria. A prebiotic composition for butyric acid bacteria includes an alginic acid having a weight average molecular weight of 10000 or less and/or a salt thereof.
The present invention addresses the problem of providing a technique that enables sympathetic nerve activation. A composition for sympathetic nerve activation, said composition containing one or more peptides selected from the group consisting of peptides consisting of any of the following amino acid sequences (SEQ ID NOS: 1-16) and peptides containing these amino acid sequences. (Amino acid sequences: VAPFPE, HLPLP, VVPPF, HQPHQPLPPT, TEDELQDK, LNPWDQ, IISQE, ANEEEY, VIPY, LPLP, VIESPPEIN, FPQY, LNVPGE, IVPNSAEE, GEPTSTPT and KFQSEEQQQ)
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 25/26 - Psychostimulants, p. ex. nicotine, cocaïne
C07K 5/103 - Tétrapeptides la chaîne latérale du premier amino-acide étant acyclique, p. ex. Gly, Ala
C07K 5/107 - Tétrapeptides la chaîne latérale du premier amino-acide contenant des carbocycles, p. ex. Phe, Tyr
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
92.
COMPOSITION, FOOD/BEVERAGE COMPOSITION THAT CONTAINS SAID COMPOSITION, AND MODIFIED MILK
Provided is a feature with which it is possible to promote propagation of probiotics using an assimilation product of κ-casein glycomacropeptides, the probiotics having little or no assimilation capacity with respect to the κ-casein glycomacropeptides. Provided is a composition that contains an assimilation product of κ-casein glycomacropeptides produced by bacteria belonging to Bifidobacterium bifidum. Also provided is a composition that contains: an assimilation product of κ-casein glycomacropeptides produced by bacteria belonging to Bifidobacterium bifidum; and bacteria belonging to Bifidobacterium breve, and/or bacteria belonging to Bifidobacterium infantis.
The present invention aims to provide a frozen dessert that can inhibit an oil and fat composition from flowing out from a frozen dessert base material. Provided is a frozen dessert including: a frozen dessert base material; and an oil and fat composition having a shear viscosity of no more than 1.4 Pa·s at 30°C and a shear viscosity of at least 4 Pa·s at 20°C. Also provided is a method for producing a frozen dessert including a frozen dessert base material and an oil and fat composition, said method including: a step A in which an oil and fat composition having shear viscosity of no more than 1.4 Pa·s at 30°C and a shear viscosity of at least 4 Pa·s at 20°C is filled into a semi-solid frozen dessert base material; and a step B in which the semi-solid frozen dessert base material into which the oil and fat composition has been filled is frozen.
Provided is a novel sleep-promoting composition.
Bifidobacterium breve as an active ingredient. The sleep-promoting composition related to the present technology may prolong a sleep time by prolonging non-REM sleep and REM sleep, reducing a spontaneous behavior amount during sleep, or reducing an awakening time during sleep. The sleep-promoting composition related to the present technology may also reduce difficulty in daytime awakening. The sleep-promoting composition related to the present technology may be used for a medical composition or a food and beverage composition.
Bifidobacterium bifidum, one or more types of probiotics having a low ability to assimilate human milk oligosaccharides, and human milk oligosaccharides. The nutritional composition as described herein may be suitably used for foods/drinks, medicines, quasi-drugs, feeds, and the like.
A23L 29/30 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sirops d'hydrate de carboneAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sucresAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des alcools de sucre, p. ex. du xylitolAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des hydrolysats d'amidon, p. ex. de la dextrine
A23C 9/123 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes ne comportant que des micro-organismes de la famille des lactobactériacéesYoghourt
A23C 9/13 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant l'emploi d'additifs
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
96.
COMPOSITION FOR BABIES AND INFANTS FOR IMPROVING MEMORY ABILITY IN CHILDHOOD
The present invention addresses the problem of providing a technique for improving memory ability in childhood, and the problem is solved by a composition for babies and infants for improving memory ability in childhood, the composition containing Bifidobacterium longum subspecies infantis as an active ingredient.
The objective of the present technology is to provide a novel composition capable of imparting thickness to a liquid without causing lumps. The present technology provides a composition which is for imparting thickness, includes xanthan gum, and has, when measured according to the laser diffraction particle size analysis measurement method: a ratio of the number of particles having a particle size of 75-150 μm (exclusive of 75) of at most 50% with respect to the total number of particles; and the ratio of the number of particles having a particle size of 150-250 μm (exclusive of 150) is at least 15% with respect to the total number of particles. This composition for imparting thickness can impart thickness to a liquid without causing lumps.
A23L 29/269 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des agents gélifiants ou épaississants d'origine microbienne, p. ex. xanthane ou dextrane
A23L 29/294 - Additifs inorganiques, p. ex. silice
Provided is a method for determining undernutrition risk and/or low body-weight child birth risk in a subject. The invention comprises determining the undernutrition risk and/or the low body-weight child birth risk in the subject using the blood albumin redox state as an indicator.
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
100.
COMPOSITION CONTAINING BIFIDOBACTERIUM BACTERIA AS ACTIVE INGREDIENT
The present invention addresses the problem of providing a composition for suppressing the adsorption of Fusobacterium bacteria by mucosal cells, and a pharmaceutical composition and food and beverage composition for the prevention and/or treatment of diseases or symptoms selected from the group consisting of ulcerative colitis, colon cancer, esophageal cancer, preterm birth, and periodontal disease, and caused by inflammation of mucosal cells. The problem is addressed by: a composition for suppressing the adsorption of Fusobacterium by mucosal cells and having Bifidobacterium bacteria as an active ingredient; and pharmaceutical composition and food and beverage composition for the prevention and/or treatment of diseases or symptoms selected from the group consisting of ulcerative colitis, colon cancer, esophageal cancer, preterm birth, and periodontal disease, and caused by inflammation of mucosal cells, the compositions having Bifidobacterium bacteria as an active ingredient.
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/02 - Préparations stomatologiques, p. ex. médicaments pour le traitement des caries, des aphtes, des périodontites
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
